Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Celladon brings in $43mm through its Series D venture round; adds $10mm

Executive Summary

Celladon Corp. has raised $43mm through what appears to be its Series D venture round. Pfizer Venture Investments led and was joined by fellow new investors Lundbeckfond Ventures, Novartis Venture Funds, H&Q Healthcare/Life Sciences Investors, and GBS Venture Partners, and all returning shareholders, including JEnterprise Partners Venture Capital, Johnson & Johnson Development Corp., and Venrock Associates. Pfizer Venture Investments, Lundbeckfond Ventures, Novartis Venture Funds, H&Q Capital Management, and GBS Venture Partners will each add one member to Celladon's board. The company is developing Phase II Mydicar for advanced heart failure with Targeted Genetics under a 2005 deal.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies